Agios Pharmaceuticals Inc
Company Profile
Business description
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Contact
88 Sidney Street
CambridgeMA02139
USAT: +1 617 649-8600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
488
Stocks News & Analysis
stocks
The best way to get rich and retire early
stocks
Investors overly negative on cheap ASX share
stocks
Overvalued US AI play reports earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,067.00 | 16.40 | -0.18% |
| CAC 40 | 8,103.85 | 17.22 | -0.21% |
| DAX 40 | 24,340.06 | 56.09 | 0.23% |
| Dow JONES (US) | 48,442.41 | 79.73 | 0.16% |
| FTSE 100 | 9,889.22 | 23.25 | 0.24% |
| HKSE | 25,817.89 | 43.75 | 0.17% |
| NASDAQ | 23,561.84 | 133.02 | 0.57% |
| Nikkei 225 | 50,481.42 | 68.55 | 0.14% |
| NZX 50 Index | 13,529.06 | 11.33 | 0.08% |
| S&P 500 | 6,909.79 | 31.30 | 0.46% |
| S&P/ASX 200 | 8,761.40 | 22.40 | -0.26% |
| SSE Composite Index | 3,923.74 | 3.76 | 0.10% |